SENSEX    73651.35       655.04    |    NIFTY    22326.9       203.25 FAQ    |    Feedback
EQUITIES
DERIVATIVES
IPO
Gainers & Losers Value & Volume Toppers 52 Weeks High/Low Advances & Declines
New High-Low
Pre-Session Mid-Session End-Session Other Markets Market Beat Stock Alert
Hot Pursuit Foreign Markets Economy News Corporate News Corporate Results
Detailed Quotes Board of Directors Balance Sheet Profit & Loss Quarterly Results Historical Price
Financial Ratios Company Background Technical Chart
Announcements Book Closure Board Meetings Bonus Issues Rights Issues
De-Listed Shares Name Change Split of Face Value Market Turnover
FII Investments MF Investments ADR Prices World Indices
Forthcoming IPOs
Open IPOs
Closed IPOs
New Listing
Basis Of Allotment Draft Prospectus New Issue Monitor
Get Quotes
Gainers
Losers
Value Toppers Advances & Declines Ticker Spot
Ticker Futures Closing Price Technical Chart Commodity News MCX Currency Futures
Get Quotes NIFTY Futures Top Traded Value Top Quantity Most Active Contracts
FII Statistics Daily Settlement Price List of Underlyings Put Call Ratio Derivative Summary
All Index Futures Top Gainers Top Losers Most Active Put Most Active Call
Highest in OI Lowest in OI Increase in OI Decrease in OI
Stock Alert
Overall view of all the recent market developments which will help in your investment decisions
Wipro in focus on multi-year engagement
13-Dec-19   08:29 Hrs IST

Wipro said that it has been awarded a strategic multi-year cyber governance, cloud and infrastructure services transformation engagement by Olympus. Headquartered in Tokyo, Olympus is a global medtech company committed to Making people's lives healthier, safer and more fulfilling.

Raymond said it has allotted 33,38,278 Equity Shares at a price of Rs 674 per Equity Share aggregating to approximately Rs 225 crore and 18,54,599 0.01% Compulsorily Convertible Preference Shares, each carrying a right to convert to one Equity Share per Preference Share, at a price of Rs 674 per Preference Share, aggregating to approximately Rs 125 crore, on preferential basis to J. K. Investo Trade (India) Limited.

Biocon and Equillium Inc. a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand. Equillium had originally secured exclusive rights to develop and commercialize Biocon's novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017.

Bank of Baroda said it has issued and allotted 65,14,65,798 equity shares of Rs 2/- each fully paid up at an issue price of Rs 107.45 per equity share (premium of Rs 105.45 per share) aggregating to Rs 7,000 crore to Government of India (Promoter) on preferential basis. Bank of Baroda has also signed the binding Share Purchase Agreement for sale of business of Bank of Baroda (Trinidad & Tobago) Limited (BOBTTL) with Ansa Merchant Bank Ltd., subject to regulatory approval.

Navin Fluorine International said the company is planning a capex program at Dahej (Gujarat) through a wholly owned subsidiary with an estimated aggregate capital outlay of over Rs 450 crore over the next 3 - 4 years. The Board of Directors has initially approved capital expenditure of approx. Rs. 90 crore for site development and related infrastructure on approx. 74 acres of land for greenfield projects at Dahej through a wholly owned subsidiary. The said capital expenditure will be funded out of its internal accruals. The development of the infrastructure will enable the Company to set up various future greenfield projects in fluorochemicals.

Infosys said its subsidiary, EdgeVerve Systems, announced partnership with IDEGO, a leading consulting firm for digital transformation, to develop and deliver innovative tech products to their customers across Latin America. Together, they will assist enterprises across telecom and financial services to help improve enterprise-wide productivity and efficiency.

Powered by Capital Market - Live News

MARKETS
TODAY'S MARKET SECTOR
BSE NSE
Currencies
Currency EUR GBP INR USD
Europe (EUR) 1.00 0.86 90.21 1.08
United Kingdom (GBP) 1.17 1.00 105.20 1.26
India (INR) 0.01 0.01 1.00 0.01
United States (USD) 0.92 0.79 83.34 1.00
Market News << ALL News
  29-Mar-2024, (10:27 )  ICRA upgrades rating..
  29-Mar-2024, (10:00 )  EIH gets approval fo..
  29-Mar-2024, (09:16 )  PNB to raise Rs 10,0..
  28-Mar-2024, (04:13 )  Bajaj Finance rallie..
 Commodities << ALL Commodities
   Attention Investor: Prevent unauthorized transactions in your trading / Demat account : Update your mobile number / e mail ids with your stock broker / deposit." | "No need to issue cheques by investors while subscribing to IPO.Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account." | "KYC is one time exercise while dealing in securities markets- once KYC is done through a SEBI registered intermediary(broker, DP, Mutual Fund etc.) you need not undergo the same process again when you approach another intermediary."
   Disclaimer   |   BSE Disclosure  |  Privacy Policy   |   Investor Protection   |    Inactive Account   |  Vernacular Language: NSE | BSE   |   Feedback   |    PMLA Policy   |   Risk Management Policy   |   Insider Trading   |   Investor Grivenances   |   Investor Complaints   |   Investor Charter   |   Rules And Regulations   |   Broker Norms   |   Terms of Use    Policies & Procedures   |   Risk Disclosure   |   Do & Don’ts   |   Rights & Obligations
  
SEBI Registration No : INZ000267132   |   BSE Clearing No : 333   
   Copyright © 2011 All rights reserved by Jaysukhlal Jagjivan Stock Broking Pvt.Ltd Designed, Developed & Powered By CMOTS INFOTECH (ISO 9001:2015 certified)